五肽 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Purity assessment for this peptide relies mainly on reversed-phase high-performance liquid chromatography. A C18 column with a water-acetonitrile gradient containing trifluoroacetic acid separates the target from truncated sequences and oxidation products. Detection near 214 nm exploits the amide backbone, while the aromatic side chains allow additional monitoring close to 280 nm. Reported purity values depend on the method, so a certificate of analysis carries weight only when gradient, column and integration parameters are given.
Mass spectrometry confirms identity and reveals structural deviations that chromatography alone can miss. Positive-mode electrospray ionisation generally yields multiply charged ions whose deconvoluted mass is checked against the theoretical value. Amino acid analysis, and enzymatic digestion with subsequent fragment mapping, provide independent confirmation of sequence and of the terminal amide. Analysts take care to separate the target from deletion sequences, which may differ by one residue and therefore by only a small mass increment.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
| Property | Value | Notes |
|---|---|---|
| Primary purity method | Reversed-phase HPLC | C18 column, water-acetonitrile gradient |
| Detection wavelength | 214 nm, optionally 280 nm | Amide backbone and aromatic side chains |
| Identity confirmation | Electrospray ionisation mass spectrometry | Deconvoluted mass compared with theory |
| Storage of solid | -20 °C or lower, dry and dark | Stability depends on residual moisture |
| Storage in solution | 2-8 °C, short term | Freeze-thaw cycling avoided |
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
在机制层面，ipamorelin 与生长激素促分泌受体 1a 型结合，该受体也介导胃饥饿素的多种效应。受体激活后，细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱，它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到，但人体数据仍然有限。
现有文献多来自小规模、短期的研究，涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏，以及重复给药后效应是否衰减，仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大，因此结论外推需谨慎。关于临床获益的确切证据尚不充分，需要更大规模的对照试验来澄清。
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
== Effectiveness == Marketing claims that Protadim can prevent or treat cancer are unproven and have been deemed fraudulent by the FDA. Research into use as a treatment for amyotrophic lateral sclerosis is of poor quality, casting doubt on its usefulness for drawing any conclusions about efficacy. In 2011, Harriet A. Hall wrote for Science-Based Medicine that "we simply don't know enough at this point to recommend Protandim for treatment or prevention of any disease, for anti-aging, for making people feel healthier or more energetic, or for anything else".
The pharmacodynamics of spironolactone are characterized by high antimineralocorticoid activity, moderate antiandrogenic activity, and weak steroidogenesis inhibition, among other more minor activities. Spironolactone is a prodrug, so most of its actions are actually mediated by its various active metabolites. The major active forms of spironolactone are 7α-thiomethylspironolactone (7α-TMS) and canrenone (7α-desthioacetyl-δ6-spironolactone). Spironolactone is a potent antimineralocorticoid. That is, it is an antagonist of the mineralocorticoid receptor (MR), the biological target of mineralocorticoids like aldosterone and 11-deoxycorticosterone. By blocking the MR, spironolactone inhibits the effects of mineralocorticoids in the body. The antimineralocorticoid activity of spironolactone is responsible for its therapeutic efficacy in the treatment of edema, high blood pressure, heart failure, hyperaldosteronism, and ascites due to cirrhosis. It is also responsible for many of the side effects of spironolactone, such as urinary frequency, dehydration, hyponatremia, low blood pressure, fatigue, dizziness, metabolic acidosis, decreased kidney function, and its risk of hyperkalemia. Due to the antimineralocorticoid activity of spironolactone, levels of aldosterone are significantly increased by the medication, probably reflecting an attempt of the body to maintain homeostasis. Spironolactone is a moderate antiandrogen. That is, it is an antagonist of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT).
The citric acid cycle is regulated mainly by the availability of key substrates, particularly the ratio of NAD+ to NADH and the concentrations of calcium, inorganic phosphate, ATP, ADP, and AMP. Citrate – the ion that gives its name to the cycle – is a feedback inhibitor of citrate synthase and also inhibits PFK, providing a direct link between the regulation of the citric acid cycle and glycolysis.
A new Familia 1000 coupé arrived in November 1965, with a 985 cc SOHC "PC" engine, and was joined by the larger Mazda Luce in 1966. Around the same time, the 800 engine was upgraded, adding three horsepower. As a number of new 1-litre vehicles were introduced by Mazda's competitors, another 987 cc OHV engine (PB) appeared in January 1967, powering new 1000 saloon and van versions. The 1-litre saloons and vans are recognizable by their broader, rounded-off rectangular headlights. Production of the saloon continued until November 1967, while the van versions continued until they were replaced in February 1968. Around 400,000 of the first Familias were built, 130,473 of which were saloons and coupés. Around 10,000 of the first generation Familias were exported, mainly to Australia and Oceania.
Sources: en.wikipedia.org
Horses are used to measure distances in horse racing – a horse length (shortened to merely a length when the context makes it obvious) equals roughly 8 feet or 2.4 metres. Shorter distances are measured in fractions of a horse length; also common are measurements of a full or fraction of a head, a neck, or a nose.
=== Comorbidity === Other psychological issues may factor into anorexia nervosa. Some pre-existing disorders can increase a person's likelihood to develop an eating disorder. Additionally, anorexia nervosa can contribute to the development of certain conditions. The presence of psychiatric comorbidity has been shown to affect the severity and type of anorexia nervosa symptoms in both adolescents and adults. Post-traumatic stress disorder remains highly prevalent among patients with anorexia nervosa, with more comorbid PTSD being associated with more severe eating disorder symptoms. Obsessive–compulsive disorder (OCD) and obsessive–compulsive personality disorder (OCPD) are highly comorbid with AN. OCD is linked with more severe symptomatology and worse prognosis. The causality between personality disorders and eating disorders has yet to be fully established. Other comorbid conditions include depression, alcoholism, substance abuse, borderline and other personality disorders, anxiety disorders, attention deficit hyperactivity disorder, and body dysmorphic disorder (BDD). Depression and anxiety are the most common comorbidities, and depression is associated with a worse outcome. Autism spectrum disorder occurs more commonly among people with eating disorders than in the general population, with about 30% of children and adults with AN likely having autism. Zucker et al. (2007) proposed that conditions on the autism spectrum make up the cognitive endophenotype underlying anorexia nervosa and appealed for increased interdisciplinary collaboration.
The Double-A classification usually hosts developing players that have been part of professional baseball for only a couple of years. These players can get to the Double-A level by earning a promotion from any of the lower-level leagues, with High-A being immediately below Double-A in the minor league hierarchy. The step up to the Double-A level can be one of the hardest promotions for such players because it is the level at which pitchers need to have a good off-speed pitch in their repertoires. In addition, it is the level where fastball-only hitters need to learn how to hit off-speed pitches, or their hopes of advancing to the majors will diminish. Some players may be placed in Double-A to begin their minor league careers, usually veterans from foreign leagues or top prospects out of college. Additionally, major league clubs sometimes send players to their Double-A team to rehabilitate from injuries. While Triple-A is the highest level in the minor leagues, players may also advance to the major leagues directly from Double-A. For example, within the Toronto Blue Jays organization, 17 position players were promoted from Double-A directly to MLB during 1978–2018; approximately one player every two seasons. As players at the Double-A level are, generally, still improving their skills, it could be argued that the pure talent level is higher in Double-A than Triple-A, where there may be some stagnation of talent.
== Distribution and habitat == Coffee senna is native to the southern United States of America, Mexico and South America, but is an aggressive, pantropical weed. In Australia it is widespread but scattered in the north of Western Australia, the Northern Territory, South Australia, Queensland and New South Wales.
Some evidence suggests that amphetamine may be more strongly modulated by ovarian sex hormones than other psychostimulants such as methylphenidate, which may result in relatively greater variability in drug response across the menstrual cycle. Although preliminary observational evidence suggests potential benefit from adjusting amphetamine doses according to menstrual cycle phases, randomized controlled trials have not evaluated this practice.
Sources: en.wikipedia.org
Results are most often expressed as a percentage of total peak area from a reversed-phase separation. That figure reflects the detection wavelength, gradient and integration choices used by the laboratory. Two valid certificates can therefore quote different values for the same material without either being incorrect.
Chromatography separates components but does not identify them. Mass measurement gives an independent check that the main peak corresponds to the expected molecular mass. Used together, the two techniques detect both impurity load and structural misassignment.
Hydrolysis and oxidation are the main degradation routes in aqueous media. Loss of the C-terminal amide and oxidation of the aromatic residues are commonly reported changes. Cool storage and short working periods limit the extent of both processes.
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.